.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Farmers Insurance
Express Scripts
Medtronic
Healthtrust
Cerilliant
Johnson and Johnson
Julphar
Merck
Cantor Fitzgerald

Generated: September 24, 2017

DrugPatentWatch Database Preview

Rasagiline mesylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for rasagiline mesylate and what is the scope of rasagiline mesylate freedom to operate?

Rasagiline mesylate
is the generic ingredient in two branded drugs marketed by Watson Labs Inc, Teva, Apotex Inc, Orchid Hlthcare, and Mylan Pharms Inc, and is included in five NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Rasagiline mesylate has one hundred and thirteen patent family members in thirty-four countries.

There are eighteen drug master file entries for rasagiline mesylate. Six suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: rasagiline mesylate

Tradenames:2
Patents:4
Applicants:5
NDAs:5
Drug Master File Entries: see list18
Suppliers / Packagers: see list6
Bulk Api Vendors: see list55
Clinical Trials: see list558
Patent Applications: see list220
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:rasagiline mesylate at DailyMed

Pharmacology for Ingredient: rasagiline mesylate

Tentative approvals for RASAGILINE MESYLATE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe0.5MGTABLET;ORAL
► Subscribe► Subscribe1MGTABLET;ORAL
► Subscribe► SubscribeEQ 1MG BASETABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Mylan Pharms Inc
RASAGILINE MESYLATE
rasagiline mesylate
TABLET;ORAL201971-002May 15, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
RASAGILINE MESYLATE
rasagiline mesylate
TABLET;ORAL201950-002Sep 12, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Watson Labs Inc
RASAGILINE MESYLATE
rasagiline mesylate
TABLET;ORAL201823-002Jul 1, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-001May 16, 2006ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006ABRXYesYes► Subscribe► Subscribe► Subscribe
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-001May 16, 2006ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Apotex Inc
RASAGILINE MESYLATE
rasagiline mesylate
TABLET;ORAL201950-001Sep 12, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006ABRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: rasagiline mesylate

Non-Orange Book Patents for Generic Ingredient: rasagiline mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,786,390 Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan► Subscribe
5,891,923 R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia► Subscribe
7,598,420Rasagiline formulations and processes for their preparation► Subscribe
5,519,061 R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof► Subscribe
5,457,133 R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them► Subscribe
6,316,504 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof► Subscribe
5,387,612 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease► Subscribe
6,956,060 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof► Subscribe
5,744,500 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof► Subscribe
5,599,991 Esylate and sulfate salts of R(+)-N-propargyl-1-aminoindan► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: rasagiline mesylate

Country Document Number Estimated Expiration
South Africa9009997► Subscribe
Japan2003160481► Subscribe
Australia6942796► Subscribe
European Patent Office0436492► Subscribe
Hungary215451► Subscribe
Hungary225859► Subscribe
Spain2586412► Subscribe
Israel184033► Subscribe
Australia2006216696► Subscribe
European Patent Office0812190► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RASAGILINE MESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00205Netherlands► SubscribePRODUCT NAME: RASAGILINE, DESGEWENST IN DE VORM VAN EENFARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/04/304/001 T/M 007 20050221
C/GB05/042United Kingdom► SubscribePRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221
2005 00040Denmark► Subscribe
2005 00039Denmark► Subscribe
191Luxembourg► Subscribe91191, EXPIRES: 20191012
/2005Austria► SubscribePRODUCT NAME: RASAGILINE; REGISTRATION NO/DATE: EU/1/04/304/001-007 20050221
C024/2005Ireland► SubscribeSPC024/2005, 20060725, EXPIRES: 20191011
0205Netherlands► Subscribe300205, 20141012, EXPIRES: 20191011
195Luxembourg► Subscribe91195, EXPIRES: 20160102
0812190/01Switzerland► SubscribeFORMER OWNER: TEVA PHARMACEUTICAL INDUSTRIES, LTD., IL
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Novartis
Moodys
Cipla
US Army
Dow
Chubb
Fish and Richardson
Cerilliant
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot